Antiintregrins - New antiplatelet agents for prevention and treatment of acute coronary syndroms;Antiintegrine - Neue plattchenfunktionshemmer zur therapie und pravention des akuten koronarsyndroms

Wiener Klinische Wochenschrift

Volumn 111, Issue 3, 1999, Pages 90-97

  Schrör, Karsten ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Abciximab; Antiplatelet agents; Atherothrombosis; GP IIb IIIa antagonists; Integrins

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; CELL ADHESION MOLECULE; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; INTEGRIN; LAMIFIBAN; SIBRAFIBAN; TICLOPIDINE; TIROFIBAN; VITRONECTIN; VON WILLEBRAND FACTOR; XEMILOFIBAN; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ARTICLE; CELL INTERACTION; CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HEART MUSCLE ISCHEMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; RECEPTOR BINDING; THROMBOCYTE AGGREGATION INHIBITION; ANIMAL; BLOOD; CORONARY ARTERY THROMBOSIS; DRUG ANTAGONISM; DRUG EFFECT; REVIEW; THROMBOCYTE AGGREGATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CORONARY THROMBOSIS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INTEGRINS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 0033548174     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Antiplatelet Trialists' Collaboration (1994) Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308: 81-106
2. Kraupp O (1973) Die pharmakodynamischen Grundlagen einer spezifischen Therapie der Koronarinsuffizienz. Wien Klin Wochenschr 85: 115-122
3. Meade TW for the Medical Research Council's General Practice Research Framework (1998) Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 351: 233-241
4. Gent M and CAPRIE Steering Committee (1996) A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329-1339
5. Coller BS (1997) Platelet GP IIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest 99: 1467-1471
6. Frishman WH, Burns B, Atac B, Alturk N, Altajar B, Lerrick K (1995) Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Am Heart J 130: 877-892
7. Adgey AA (1998) An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Eur Heart J 19 [Suppl] D: D10-D21
8. Chesebro JH, Badimon JJ (1998) Platelet glycoprotein IIb/IIIa receptor blockade in unstable coronary disease (Editorial). N Engl J Med 338: 1539-1541
9. Kleiman NS, Lincoff M, Ohman M, Harrington A (1998) Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: Pathophysiological foundation and clinical findings. Am Heart J 136: S32-S42
10. Théroux P (1998) Oral inhibitors of platelet membrane receptor glycoprotein IIb/IIIa in clinical cardiology: Issues and opportunities. Am Heart J 135: S107-S112
11. Topol EJ (1998) The future of antithrombotic and antiplatelet therapy for ischemic heart disease. Am Heart J 136 [Suppl]: S66-S68
12. Topol EJ (1998) Toward a new frontier in myocardial reperfusion therapy. Circulation 97: 211-218
13. Gawaz M, Neumann F-J, Ott I, Schiessler A, Schömig A (1996) Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 93: 229-237
14. 3) mediates platelet adhesion to the luminal aspect of endothelial cells. Implications for reperfusion in acute myocardial infarction. Circulation 96: 1809-1818
15. Schrör K (1995) Comparative pharmacology of antiplatelet agents. Drugs 50: 7-28
16. Weinberger I, Fuchs J, Davidson E, Rotenberg Z (1992) Circulating aggregated platelets, number of platelets per aggregate and platelet size during acute myocardial infarction. Am J Cardiol 70: 981-983
17. Schrör K (1998) Atherothrombose als pathologische Interaktion zwischen Thrombozyten und Gefäßwand. Hämostaseologie 18: 156-160
18. Coller BS, Scudder LE, Beer J, Gold HK, Folts JD et al (1991) Monoclonal antibodies to platelet GP IIb/IIIa as antithrombotic agents. Ann NY Acad Sci 614: 193-213
19. Coller BS (1995) Blockade of platelet GP IIb/IIIa receptors as an antithrombotic strategy. Circulation 92: 2373-2380
20. 3 integrin, and GPIbα. J Exp Med 187: 329-339
21. Hynes RO (1987) Integrins: a family of cell surface receptors. Cell 48: 549-554
22. Perutelli P, Mori PG (1992) Biochemical and molecular basis of Glanzmann's thrombasthenia. Haematologica 77: 421-426
23. Calvete JJ (1994) Clues for understanding the structure and function of a prototypic human integrin: the platelet glycoprotein IIb/IIIa complex. Thromb Haemost 72: 1-15
24. 3 integrins in hemostasis and vascular biology. Thromb Haemost 74: 149-155
25. 3integrins. J Biol Chem 271: 10365-10371
26. Sheu JR, Ko WC, Hung WC, Peng HC, Huang TF (1997) Interaction of thrombin-activated platelets with extracellular matrices (fibronectin and vitronectin): comparison of the activity of Arg-Gly-Asp-containing venom peptides and monoclonal antibodies against glycoprotein IIb/IIIa complex. J Pharm Pharmacol 49: 78-84
27. Hoekstra WJ, Poulter BL (1998) Combinatorial chemistry techniques applied to nonpeptide integrin antagonists. Curr Med Chem 5: 195-204
28. Niewiarowski S, McLane MA, Kloczewiak M, Stewart GJ (1994) Disintegrins and other naturally occurring antagonists of platelet fibrinogen receptors. Sem Hematol 31: 289-300
29. Ruoslahti E (1996) RGD and other recognition sequences for integrins. Ann Rev Cell Dev Biol 12: 697-715
30. Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, et al (1994) Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 90: 1757-1764
31. Konstantopoulos K, Kamat SG, Schafer AI, et al (1995) Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty. Circulation 91: 1427-1431
32. EPIC Investigators (1994) Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330: 956-961
33. (The) EPILOG Investigators (1997) Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336: 1689-1696
34. (The) CAPTURE Investigators (1997) Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 349: 1429-1435
35. Brener SJ, Barr LA, Burchenal JEB, Katz St, George BS, Jones AA, et al for the RAPPORT Investigators (1998) Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 98: 734-741
36. Phillips DR, Scarborough RM (1997) Clinical pharmacology of eptifibatide. Am J Cardiol 80/4A: 11B-20B
37. Barrett JS, Murphy G, Peerlinck K, De Lepeleire I, Gould RJ, Panebianco D, et al (1994) Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clin Pharmacol Ther 56: 377-388
38. 2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty. Arterioscler Thromb Vasc Biol 17: 3224-3229
39. Kouns WC, Kirchhofer D, Hadvary P, Edenhofer A, Weller T, Pfenninger G, Baumgartner HR, Jennings LK, Steiner B (1992) Reversible conformational changes induced in glycoprotein IIb/IIIa by a potent and selective peptidomimetic inhibitor. Blood 80: 2539-2547
40. (The) IMPACT-II Investigators (1997) Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 349: 1422-1428
41. (The) RESTORE Investigators (1997) Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 96: 1445-1453
42. (The) PRISM-Study Investigators (1998) A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 338: 1498-1505
43. (The) PARAGON Investigators (1998) International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin or both in unstable angina. Circulation 97: 2386-2395
44. (The) PRISM-PLUS Study Investigators (1998) Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 338: 1488-1497
45. (The) PURSUIT Trial Investigators (1998) Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 339: 436-443
46. Harrington RA, Kleiman NS, Granger CB, Ohman EM, Berkowitz SD (1998) Relation between inhibition of platelet aggregation and clinical outcomes. Am Heart J 136: 543-550
47. Frederick LG, Suleymanov OD, Szalony JA, Taite BB, Salvers AK, King LW et al (1998) Protective effect of oral xemilofiban in arterial thrombosis in dogs. Increased activity in combination with aspirin. Circulation 98: 813-820
48. Umemura K, Kondo K, Ikeda Y, Nakashima M (1997) Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban. Thromb Haemost 78: 1381-1384
49. 3) inhibitors. Blood 92: 3240-3249
50. Mousa SA, Forsythe M, Lorelli W, Bozarth J, Xue C-B, Wityak J, et al (1996) Novel nonpeptide antiplatelet glycoprotein IIb/IIIa receptor antagonist, DMP754: receptor binding affinity and specifity. Cor Artery Dis 7: 767-774
51. Simpfendorfer C, Kottke-Marchant K, Lowrie M, Anders RJ, Burns DM, Miller DP, et al (1997) First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions. Circulation 96: 76-81
52. Cannon ChrP, McCabe CH, Borzak St, Henry TD, Tischler MD, Mueller HS, et al for the TIMI 12 investigators (1998) Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome. Results of the TIMI 12 trial. Circulation 97: 340-349
53. Quinn M, Fitzgerald DJ (1998) Long-term administration of glycoprotein IIb/IIIa antagonists. Am Heart J 135: S113-S118
54. Storey RF, Wilcox RG, Heptinstall S (1998) Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregale formation and effect of anticoagulant on antagonist potency. Circulation 98: 1616-1621
55. Peerlinck K, De Lepeleire I, Goldberg M, Farrell D, Barrett J, Hand E et al (1993) MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation 88: 1512-1517